GLP 1s effectiveness at blood pressure control on par with traditional anti hypertensives, tracks well with % weight loss. In someone with hypertension due to their underlying obesity, why not Michael Weintraub, MD Retatrutide vs Tirzepatide vs Semaglutide comparison Voy Emerging incretin and multi agonist based treatments the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio kidney liver metabolic diseases and beyond Metabolism Clinical and Experimental Once weekly mazdutide, a glucagon like peptide 1 and glucagon receptor dual agonist, provided clinically relevant reduction in body weight in Chinese adults with obesity or overweight. Full GLORY 1 trial results: https: nej.md 4koUvaP Incretin based therapies for the treatment of obesity related diseases npj Metabolic Health and Disease